You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三大線上醫療股飆13%至20% 新冠疫苗獲批三葉草-B(02197.HK)漲逾7%
內地疫情持續,並審慎放寬防疫措施,或刺激視像診症需求增加。國家衛健委最新通報,昨日(4日)新增4,247宗本土新冠肺炎確診病例,25,477宗本土無症狀感染者。 三大線上醫療股受追捧,藍籌阿里健康(00241.HK)今日(5日)高開5.93%,最高見8.57元。現報8.53元,升17.7%,成交1.22億股,涉資9.9億元。平安好醫生(01833.HK)最高見27.5元。現報27.45元,升19.6%,成交2,290.8萬股,涉資5.91億元。京東健康(06618.HK)最高見81.4元。現報81.05元,升13.4%,成交1,370.46萬股,涉資10.77億元。 另三葉草生物-B(02197.HK)現升逾7%,其新冠疫苗SCB-2019(CpG 1018/鋁佐劑)已獲內地有關部門評估並在內地被納入緊急使用。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account